How Certain Psychedelics Produce Brain And Behavior Changes: UCL Leads New Study

The University College London (UCL) is conducting a new research project called “Understanding Neuroplasticity Induced by Tryptamines (UNITy)” aimed at assessing brain changes and neuroplasticity induced by these kinds of psychedelic compounds. 

In the context of this brain-imaging study, psychedelics company Small Pharma Inc. DMTTF will provide its proprietary intravenous (IV) formulation of DMT, SPL026, to be used by the UCL’s department of psychology and language science. The goal is to provide an understanding of the effects of DMT in brain function, behavior and well-being. 

The UNITy Project will use functional Magnetic Resonance Imaging (fMRI) to image the brain before, during and after a DMT or placebo infusion. Follow-ups with study participants will be done for up to nine months.

UCL associate professor Ravi Das praised Small Pharma, and said there is an “urgent need for new, effective and lasting mental health treatments.” 

While previous clinical research into psychedelics has been promising “there is a lack of mechanism-focused, well-controlled research into how, why and in whom these drugs work,” he explained. UCL expects the present project will take “major steps forward” in progressing the understanding of how DMT affects the brain and behavior.

Small Pharma CMO and CSO Carol Routledge added: “Driving forward scientific research and excellence is really important to Small Pharma, so we are delighted to support UCL on this large-scale neuroimaging study.” 

The company hopes the findings will provide an increased understanding of the mechanistic effects of DMT in the brain as well as which patient populations could benefit most from DMT-based therapies.

Photo courtesy of CDC on Pexels and Jynto on Wikimedia Commons.

Market News and Data brought to you by Benzinga APIs
Posted In: CannabisNewsPenny StocksPsychedelicsOfferingsContractsManagementTop StoriesMarketsDMT-Assisted TherapyfMRITryptaminesUniversity College London
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

The Benzinga Cannabis Capital Conference is coming to Florida

The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.

Get your tickets now on – Prices will increase very soon!